Search Within

Niloufer Khan

Formats
  1. Meeting Abstract (28)
  2. Journal Article (15)
  3. Editorial (2)
  4. Correspondence (1)
  5. Miscellaneous (1)
  6. Review (1)
Groups
  1. Hematologic Malignancies, Division of (48)
  2. Survivorship Research (48)
  3. Department of Medicine (44)
  4. Center for Hematologic Malignancies (41)
  5. Lymphoma (34)
  6. Population Sciences Research Program (32)

More Groups

People
  1. Steven Horwitz (28)
  2. Alison Moskowitz (26)
  3. Andrew Zelenetz (17)
  4. Matthew Matasar (17)
  5. Anita Kumar (15)
  6. Ariela Noy (15)

More People

Years
  1. 2023 (5)
  2. 2022 (12)
  3. 2021 (13)
  4. 2020 (4)
  5. 2019 (7)
  6. 2018 (6)

More Years

Publications
  1. Blood (20)
  2. Journal of Clinical Oncology (4)
  3. Hematological Oncology (3)
  4. Leukemia and Lymphoma (3)
  5. Biology of Blood and Marrow Transplantation (2)
  6. Blood Advances (2)

More Publications

Publishers
  1. American Society of Hematology (22)
  2. Elsevier Inc. (5)
  3. American Society of Clinical Oncology (4)
  4. Taylor & Francis Group (4)
  5. Wiley Blackwell (3)
  6. Springer (1)

More Publishers

Results (48)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • TP53 mutations identify high-risk peripheral T-cell lymphoma patients treated with CHOP-based chemotherapy
    Meeting Abstract

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Maccaro, C.; Galasso, N.; Sauter, C. S.; Neuman, R.; Khan, N.; Moskowitz, A. J.; Dogan, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience
    Meeting Abstract

    Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of choice of platinum-based salvage therapy on CNS relapse in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Buege, M. J.; Dao, P.; Dematteo, R. G.; LeVoir, A.; Pak, T.; Batlevi, C. L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Khimani, F.; Shustov, A. R.; Shadman, M.; Ruan, J.; Moskowitz, A. J.; Straus, D. J.; Kumar, A.; Sauter, C. S.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Dermatologic adverse events of brentuximab vedotin: Characteristics, management, and their relationship with dose regimen
    Meeting Abstract

    Oh, Y.; Bang, A.; Kurtansky, N.; Khan, N.; Pulitzer, M.; Noor, S.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • How we treat mycosis fungoides and Sézary syndrome
    Journal Article

    Khan, N.; Noor, S. J.; Horwitz, S.
    Clinical Advances in Hematology & Oncology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S. V.; Drill, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase II trial of reduced dose brentuximab vedotin for cutaneous T‐cell lymphomas
    Meeting Abstract

    Khan, N.; Noor, S.; Geller, S.; Khodadoust, M. S.; Kheterpal, M.; Hancock, H.; Davey, T.; Ryu, S.; Perez, L.; Lares, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • The experience of financial toxicity among advanced melanoma patients treated with immunotherapy
    Journal Article

    Thom, B.; Mamoor, M.; Lavery, J. A.; Baxi, S. S.; Khan, N.; Rogak, L. J.; Sidlow, R.; Korenstein, D.
    Journal of Psychosocial Oncology (2021)

    Fulltext@MSK | Save
  • Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: A multicenter observational study
    Journal Article

    Khan, N.; Lindner, S.; Gomes, A. L. C.; Devlin, S. M.; Shah, G. L.; Sung, A. D.; Sauter, C. S.; Landau, H. J.; Dahi, P. B.; Perales, M. A.; more...
    Blood (2021)

    Fulltext@MSK | Save